Global Huntington’s Disease Market - 2025-2033

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	168 Pages	DataM Intelligence 4Market Research LLP	April, 2025	DTAM20040998

Best Price Guarantee
Price	from $4,350
Length	168 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	April, 2025
SKU	DTAM20040998

Global Huntington’s Disease Market - Overview

The global Huntington’s disease market size reached US$ 455.65 million in 2024 and is expected to reach US$ 3,230.84 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

The Huntington’s disease market is being driven by increasing research and development efforts focused on innovative therapies, alongside growing public awareness and education about the disorder. North America is expected to maintain a leading position in the global market due to strong healthcare infrastructure and ongoing clinical advancements, while the Asia-Pacific region is projected to experience the fastest growth, supported by expanding healthcare access and rising investment in neurological research.

Global Huntington’s Disease Market Dynamics - Drivers & Restraints

Rising Research and Development is Expected to Propel the Huntington’s Disease Market

With increased focus on the genetic basis of the disease, therapies such as gene silencing and antisense oligonucleotides (ASOs), pharmaceutical companies, and research institutions continue to advance innovative therapeutic strategies. For instance, in June 2024, Wave Life Sciences announced encouraging results from its Phase 1b/2a SELECT-HD trial of WVE-003, an allele-selective ASO designed to reduce mutant huntingtin (mHTT) protein while preserving healthy wild-type HTT. The therapy showed a 46% reduction in mHTT in cerebrospinal fluid compared to placebo and demonstrated a significant correlation with slower brain atrophy, a biomarker linked to disease progression.

Additionally, organizations continue to invest heavily in HD research, accelerating the development of disease-modifying treatments. For instance, in January 2025, Brain Canada, the Huntington Society of Canada (HSC), and the River Philip Foundation jointly announced a new investment of $1.2 million to support research focused on Huntington’s disease. These advancements are expanding the therapeutic landscape and attracting regulatory interest, positioning R&D as a key force driving future growth in the Huntington’s disease market.

Huntington’s Disease Approved Drugs:

High Cost of Treatment is Expected to Hamper the Huntington’s Disease Market

The high cost of treatment could limit patient access and place a substantial financial burden on healthcare systems. Currently available therapies, such as Austedo (deutetrabenazine) and Xenazine (tetrabenazine), which are used to manage symptoms like chorea, can cost tens of thousands of dollars annually. These factors are expected to have a significant impact on the overall market growth.

Global Huntington’s Disease Market - Segment Analysis

The global Huntington’s disease market is segmented based on disease type, treatment, route of administration, and region.

Treatment:

The symptomatic treatment segment is expected to hold 52.4% of the global Huntington’s disease market

The symptomatic treatment segment is expected to dominate the Huntington’s disease market due to the well-established role of medications in managing hallmark symptoms, particularly chorea. Drugs such as Xenazine (tetrabenazine) and Austedo (deutetrabenazine) remain first-line therapies, offering substantial improvements in quality of life by reducing involuntary movements.

For instance, in Q2 2024, Teva Pharmaceutical Industries reported a 32% increase in quarterly U.S. sales of Austedo, reaching $407 million, highlighting its strong market demand and clinical relevance. Moreover, for instance, in August 2023, the FDA approved INGREZZA (valbenazine), developed by Neurocrine Biosciences, for the treatment of chorea associated with Huntington’s disease, further reinforcing the strength and expansion of symptomatic treatment options.

This dominance is further supported by disease prevalence data. For instance, according to the National Institute of Health in 2022, the diagnosed prevalence was estimated to be 8.2 to 9.0 per 100,000 in the United States. The growing pipeline of symptomatic therapies and their proven effectiveness make this segment likely to retain the largest market share as demand for symptom relief continues to rise.

Global Huntington’s Disease Market - Geographical Analysis

North America is expected to hold 39.7% of the global Huntington’s disease market

North America is expected to maintain a dominant position in the global Huntington’s disease (HD) treatment market due to its advanced healthcare infrastructure, high disease prevalence, and continuous research advancements. In recent years, significant developments in the region have further solidified this position. The U.S. Food and Drug Administration (FDA) has approved several treatments for symptomatic management of HD, including Austedo and Xenazine.

More recently, in August 2023, the FDA approved INGREZZA (valbenazine) for treating chorea associated with HD, based on positive results from the KINECT-HD Phase 3 study.

Additionally, companies are strategically partnering with each other to become prominent players in the market. For instance, UniQure reached an agreement with the FDA in December 2024 for the potential accelerated approval of its gene therapy AMT-130, aimed at addressing the root cause of HD.

Moreover, in December 2024, PTC Therapeutics partnered with Novartis in a licensing agreement valued at up to $2.9 billion for the development of PTC518, a drug targeting the mutated Huntingtin protein.

These efforts, along with proactive organizations like the Huntington Society of Canada, which works to train neurologists and improve care, position North America as a leader in advancing the treatment landscape for Huntington's disease.

Asia-Pacific is expected to hold 25.6% of the global Huntington’s disease market

The Asia-Pacific is expected to be the fastest-growing region in the Huntington’s disease market. This growth is attributed to the rising disease awareness, improved healthcare infrastructure, and increasing funding in research and therapeutic trials are major contributions.

Global Huntington’s Disease Market - Competitive Landscape

Manufacturers

Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., and Neurocrine Biosciences, Inc., among others.

Global Huntington’s Disease Market - Key Developments
• In September 2023, Ionis Pharmaceuticals, Inc. announced a collaboration with Roche focused on an early-stage RNA-targeting investigational therapy for Huntington’s disease. Under the agreement, Roche will have exclusive global rights and will lead clinical development, manufacturing, and commercialization if the treatment is approved. The partnership combines Ionis’ RNA-based drug discovery expertise with Roche’s global capabilities in neurological therapeutics.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Huntington’s disease market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

1. Market Introduction and Scope: 1.1. Objectives of the Report; 1.2. Report Coverage & Definitions; 1.3. Report Scope
2. Executive Insights and Key Takeaways: 2.1. Market Highlights and Strategic Takeaways; 2.2. Key Trends and Future Projections; 2.3. Snippet by Disease Type; 2.4. Snippet by Treatment; 2.5. Snippet by Route of Administration; 2.6. Snippet by Region
3. Dynamics: 3.1. Impacting Factors; 3.1.1. Drivers; 3.1.1.1. Rising Research and Development; 3.1.1.2. Rising Awareness and Patient Advocacy; 3.1.1.3. XX; 3.1.2. Restraints; 3.1.2.1. High Cost of Treatment; 3.1.2.2. Stringent Regulatory Framework; 3.1.2.3. XX; 3.1.3. Opportunity; 3.1.3.1. Expansion into Emerging Markets; 3.1.3.2. XX; 3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook: 4.1. Market Leaders and Pioneers; 4.1.1. Emerging Pioneers and Prominent Players; 4.1.2. Established Leaders with the Largest Marketing Brand; 4.1.3. Market Leaders with Established Products; 4.2. Latest Developments and Breakthroughs; 4.3. Regulatory and Reimbursement Landscape; 4.3.1. North America; 4.3.2. Europe; 4.3.3. Asia Pacific; 4.3.4. Latin America; 4.3.5. Middle East & Africa; 4.4. Porter’s Five Forces Analysis; 4.5. Supply Chain Analysis; 4.6. Patent Analysis; 4.7. SWOT Analysis; 4.8. Pipeline Analysis; 4.9. Epidemiology Analysis; 4.10. Unmet Needs and Gaps; 4.11. Recommended Strategies for Market Entry and Expansion; 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts; 4.13. Pricing Analysis and Price Dynamics; 4.14. Key Opinion Leaders
5. Huntington’s Disease Market Disease Type Outlook: 5.1. Introduction; 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type; 5.1.2. Market Attractiveness Index, By Disease Type; 5.2. Adult Onset*; 5.2.1. Introduction; 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 5.3. Early Onset
6. Huntington’s Disease Market Treatment Outlook: 6.1. Introduction; 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 6.1.2. Market Attractiveness Index, By Treatment; 6.2. Symptomatic Treatment*; 6.2.1. Introduction; 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 6.3. Disease-modifying Therapies
7. Huntington’s Disease Market Route of Administration Outlook: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 7.1.2. Market Attractiveness Index, By Route of Administration; 7.2. Oral*; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Parenteral; 7.4. Other
8. Huntington’s Disease Market, By Regional Market Analysis and Growth Opportunities: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 8.1.2. Market Attractiveness Index, By Region; 8.2. North America; 8.2.1. Introduction; 8.2.2. Key Region-Specific Dynamics; 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type; 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 8.2.6.1. U.S.; 8.2.6.2. Canada; 8.2.6.3. Mexico; 8.3. Europe; 8.3.1. Introduction; 8.3.2. Key Region-Specific Dynamics; 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type; 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 8.3.6.1. Germany; 8.3.6.2. UK; 8.3.6.3. France; 8.3.6.4. Spain; 8.3.6.5. Italy; 8.3.6.6. Rest of Europe; 8.4. Asia-Pacific; 8.4.1. Introduction; 8.4.2. Key Region-Specific Dynamics; 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type; 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 8.4.6.1. China; 8.4.6.2. India; 8.4.6.3. Japan; 8.4.6.4. South Korea; 8.4.6.5. Rest of Asia-Pacific; 8.5. South America; 8.5.1. Introduction; 8.5.2. Key Region-Specific Dynamics; 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type; 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 8.5.5.1. Brazil; 8.5.5.2. Argentina; 8.5.5.3. Rest of South America; 8.6. Middle East and Africa; 8.6.1. Introduction; 8.6.2. Key Region-Specific Dynamics; 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type; 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. Competitive Landscape and Market Positioning: 9.1. Competitive Overview and Key Market Players; 9.2. Market Share Analysis and Positioning Matrix; 9.3. Strategic Partnerships, Mergers & Acquisitions; 9.4. Key Developments in Product Portfolios and Innovations; 9.5. Company Benchmarking
10. Company Profiles: Key Players; 10.1. Teva Pharmaceutical Industries Ltd.*; 10.1.1. Company Overview; 10.1.2. Product Portfolio; 10.1.2.1. Product Description; 10.1.2.2. Product Key Performance Indicators (KPIs); 10.1.2.3. Historic and Forecasted Product Sales; 10.1.2.4. Product Sales Volume; 10.1.3. Financial Overview; 10.1.3.1. Company Revenue; 10.1.3.2. Geographical Revenue Shares; 10.1.3.3. Revenue Forecasts; 10.1.4. Key Developments; 10.1.4.1. Mergers & Acquisitions; 10.1.4.2. Key Product Development Activities; 10.1.4.3. Regulatory Approvals, etc.; 10.1.5. SWOT Analysis; 10.2. Bausch Health Companies Inc.; 10.3. Neurocrine Biosciences, Inc.; Emerging Players; 10.4. Annexon Inc.; 10.5. AskBio Inc.; 10.6. SOM Innovation Biotech S.A.; 10.7. Prilenia Therapeutics B.V.; 10.8. Sage Therapeutics; LIST NOT EXHAUSTIVE
11. Assumptions and Research Methodology: 11.1. Data Collection Methods; 11.2. Data Triangulation; 11.3. Forecasting Techniques; 11.4. Data Verification and Validation
12. Appendix: 12.1. About Us and Services; 12.2. Contact Us